announced the expansion of its industry-leading formulary of more than a dozen medications to include compounded oral semaglutide dissolving tablets. This needle-free option requires no ...

This practice is now reflected in the inclusion of Novo’s entire semaglutide franchise—Type 2 diabetes injection Ozempic and oral tablet Rybelsus, plus weight-loss injection Wegovy.

Semaglutide is a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor mimicking its activity. GLP-1 is an incretin hormone and enterogastrone that stimulates insulin ...